NEW YORK (GenomeWeb) – The Association of Community Cancer Centers (ACCC), a cancer care provider advocacy group, announced today that Pfizer will provide $1.5 million in grant funding to support initiatives integrating BRCA testing into patient care plans.
The funding, which is being provided under the Pfizer Independent Grants for Learning and Change program, will provide up to $150,000 to individual grant awardees. It is only available to ACCC-member cancer programs and practices.
"We are pleased to partner with ACCC on this grant program designed to tackle access challenges to BRCA testing, which will hopefully result in breast cancer patients having more information about their diagnoses and enable them to make more educated decisions about their care," Julia Perkins Smith, North America medical vice president of Pfizer oncology, said in a statement.
Pfizer is currently developing the PARP inhibitor talazoparib for breast cancer patients with germline BRCA mutations. The drug was recently shown to reduce the risk of disease progression by 46 percent versus chemotherapy in a Phase III study.